Literature DB >> 16750195

Adenosine A1 receptors are crucial in keeping an epileptic focus localized.

Denise E Fedele1, Tianfu Li, Jing Q Lan, Bertil B Fredholm, Detlev Boison.   

Abstract

Adenosine is an endogenous neuromodulator with anticonvulsant and neuroprotective properties presumably mediated by activation of adenosine A1 receptors (A1Rs). To study the involvement of A1Rs in neuroprotection during epileptogenesis, we induced status epilepticus by a unilateral intrahippocampal kainic acid (KA) injection (1 nmol) in wild-type C57BL/6 and homozygous adenosine A1R knock out (A1R-KO) mice of the same genetic background. Whereas the KA injection caused non-convulsive status epilepticus in wild-type mice, in A1R-KO mice KA induced status epilepticus with severe convulsions and subsequent death of the animals within 5 days. 24 h after KA injection, brains from wild-type C57BL/6 mice were characterized by slight neuronal cell loss confined to the immediate location of the KA injection. In contrast, KA-injected A1R-KO mice displayed massive neuronal cell loss in the ipsilateral hippocampus, and, importantly, the contralateral hippocampus was also affected with significant cell loss in the hilus and in the CA1 region of the pyramidal cell layer. We conclude that activation of A1 receptors by ambient adenosine is crucial in keeping epileptic foci localized. These results open up a new dimension of the A1 receptor's role in controlling excitotoxic cell death and further demonstrate its importance in preventing the progression of status epilepticus to lethal consequences.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16750195     DOI: 10.1016/j.expneurol.2006.02.133

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  68 in total

1.  Rethinking the purinergic neuron-glia connection.

Authors:  Bertil B Fredholm
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

Review 2.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

3.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

4.  Intracellular acidification causes adenosine release during states of hyperexcitability in the hippocampus.

Authors:  Chris G Dulla; Bruno G Frenguelli; Kevin J Staley; Susan A Masino
Journal:  J Neurophysiol       Date:  2009-07-22       Impact factor: 2.714

Review 5.  Are purines mediators of the anticonvulsant/neuroprotective effects of ketogenic diets?

Authors:  Susan A Masino; Jonathan D Geiger
Journal:  Trends Neurosci       Date:  2008-05-09       Impact factor: 13.837

Review 6.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 7.  Glial adenosine kinase--a neuropathological marker of the epileptic brain.

Authors:  Eleonora Aronica; Ursula S Sandau; Anand Iyer; Detlev Boison
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

Review 8.  Adenosine and Ketogenic Treatments.

Authors:  David N Ruskin; Masahito Kawamura; Susan A Masino
Journal:  J Caffeine Adenosine Res       Date:  2020-09-16

Review 9.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

10.  Release of adenosine and ATP during ischemia and epilepsy.

Authors:  Nicholas Dale; Bruno G Frenguelli
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.